One of the most significant – and relatively recent – innovations in the treatment of cancer are so-called immuno-oncology (IO) drugs. As today’s article explains, these drugs “enlist a patient’s immune system in the fight, giving it marching orders to tackle cancer cells…Under the right circumstances, the best IO performers can make traditional chemotherapy or surgery far more effective, or potentially even replace them”. For more on the potential of IO drugs to become “miracle” treatments for a range of cancers – and some pharmaceutical companies experiencing early success in the space – CLICK HERE.
More than 10 years into this bull market, Buy and Outperform analyst ratings generally come with implied upside potential of 8% to 10%. However, the author of today’s article notes that “One area of the market that can see much greater upside opportunities, which also implies a greater risk, is the biotech and emerging pharmaceutical stocks” – and he proceeds to highlight 20 biotech and pharma stocks that have seen analyst calls since January 1st that suggest much larger upside potential. For more, CLICK HERE.
Despite the market’s recent drop brought on by concerns over escalating trade tensions between the U.S. and China, it is hard for investors to find value plays amongst stocks. There is, however, still value to be had – and today’s article highlights three undervalued stocks to consider. Among them is a mid-cap stock carving out a niche in what the author notes “is the fastest-growing space within the pharmaceutical industry”: oncology. For more on these three value stocks, CLICK HERE.